WO2006024931A3 - Therapeutic combinations comprising a selective estrogen receptor modulator and a selective androgen receptor modulator - Google Patents

Therapeutic combinations comprising a selective estrogen receptor modulator and a selective androgen receptor modulator Download PDF

Info

Publication number
WO2006024931A3
WO2006024931A3 PCT/IB2005/002592 IB2005002592W WO2006024931A3 WO 2006024931 A3 WO2006024931 A3 WO 2006024931A3 IB 2005002592 W IB2005002592 W IB 2005002592W WO 2006024931 A3 WO2006024931 A3 WO 2006024931A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor modulator
selective
phenyl
treat
androgen receptor
Prior art date
Application number
PCT/IB2005/002592
Other languages
French (fr)
Other versions
WO2006024931A2 (en
Inventor
Hua Zhu Ke
David Duane Thompson
Original Assignee
Pfizer Prod Inc
Hua Zhu Ke
David Duane Thompson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc, Hua Zhu Ke, David Duane Thompson filed Critical Pfizer Prod Inc
Publication of WO2006024931A2 publication Critical patent/WO2006024931A2/en
Publication of WO2006024931A3 publication Critical patent/WO2006024931A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

This invention relates to a pharmaceutical combination of a selective estrogen receptor modulator (SERM) and a selective androgen receptor modulator (SARM). Particularly, this invention relates to a pharmaceutical composition comprising cis-6-phenyl-5-(4-(2-pyrrolidin-1-yl-ethoxy)-phenyl)-5,6,7,8­tetrahydronapthalene-2-ol, or a pharmaceutically acceptable salt thereof; and a selective androgen receptor modulator. This invention also relates to methods of treatment using the pharmaceutical composition comprising cis-6-phenyl-5-(4-(2-pyrrolidin-1-yl-ethoxy)-phenyl)-5,6,7,8-tetrahydronapthalene­2-ol, or a pharmaceutically acceptable salt thereof; and a selective androgen receptor modulator. Particularly, this invention is directed to methods to prevent and/or restore age-related decline in muscle mass and strength, treat a wasting disease, treat a condition that prevents with low bone mass, increase muscle mass, increase lean body mass, decrease fat body mass, treat bone fracture and muscle damage and treat female sexual dysfunction in mammals, including humans.
PCT/IB2005/002592 2004-08-31 2005-08-19 Therapeutic combinations comprising a selective estrogen receptor modulator and a selective androgen receptor modulator WO2006024931A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60592504P 2004-08-31 2004-08-31
US60/605,925 2004-08-31

Publications (2)

Publication Number Publication Date
WO2006024931A2 WO2006024931A2 (en) 2006-03-09
WO2006024931A3 true WO2006024931A3 (en) 2006-05-26

Family

ID=35735140

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/002592 WO2006024931A2 (en) 2004-08-31 2005-08-19 Therapeutic combinations comprising a selective estrogen receptor modulator and a selective androgen receptor modulator

Country Status (2)

Country Link
TW (1) TW200621231A (en)
WO (1) WO2006024931A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2447061C1 (en) * 2010-10-22 2012-04-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Ярославский государственный технический университет"(ЯГТУ) Novel 4-(azacycloalkyl)phthalonitriles and synthesis method thereof
US20150071857A1 (en) * 2012-03-07 2015-03-12 Ligand Pharmaceuticals, Inc. Steroid hormone and cholesterol pathways as one unified homeostatic system
EP3094323A4 (en) 2014-01-17 2017-10-11 Ligand Pharmaceuticals Incorporated Methods and compositions for modulating hormone levels
US20230012570A1 (en) * 2019-11-20 2023-01-19 Medshine Discovery Inc. Bicyclic compound used as selective androgen receptor modulator

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999065486A1 (en) * 1998-06-16 1999-12-23 Pfizer Products, Inc. Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating musculoskeletal frailty
WO2003092588A2 (en) * 2002-04-30 2003-11-13 Merck & Co., Inc. 4-azasteroid derivatives as androgen receptor modulators

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999065486A1 (en) * 1998-06-16 1999-12-23 Pfizer Products, Inc. Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating musculoskeletal frailty
WO2003092588A2 (en) * 2002-04-30 2003-11-13 Merck & Co., Inc. 4-azasteroid derivatives as androgen receptor modulators

Also Published As

Publication number Publication date
WO2006024931A2 (en) 2006-03-09
TW200621231A (en) 2006-07-01

Similar Documents

Publication Publication Date Title
WO2004071529A3 (en) Uses of anti-insulin-like growth factor i receptor antibodies
WO2012005500A3 (en) Time-delayed sustained release pharmaceutical composition comprising dapoxetine for oral administration
WO2005107726A3 (en) Method for the treatment of back pain
WO2007025005A3 (en) Sustained release formulations of nalbuphine
WO2004041067A3 (en) Prevention and treatment of synucleinopathic disease
PT2359856T (en) Formulation of human antibodies for treating tnf-alpha associated disorders
MY136841A (en) Carbamate-substituted pyrazolopyridines
WO2004019884A3 (en) Agents and methods for enhancing bone formation
EA200600820A1 (en) METHODS OF TREATMENT, MODIFICATION AND ELIMINATION OF PATIENTS USING 1-OXO-2- (2,6-DIOXOPYPERIDIN-3-IL) -4-METHYLISYNDOLINE
MXPA04003666A (en) Use of flibanserin in the treatment of sexual disorders.
WO2007049098A3 (en) Therapeutic formulations for the treatment of beta-amyloid related diseases
MXPA06013133A (en) Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction.
WO2008116890A3 (en) Pharmaceutical compositions comprising flibanserin and a further agent in the treatment of sexual disorders
WO2004005324A3 (en) Peptide composition for treatment of sexual dysfunction
ZA200605555B (en) Compositions and methods of administering tubulin binding agents for the treatment of ocular disease
HK1105201A1 (en) Muscle relaxation accelerator and therapeutic agent for muscular tissue diseases such as muscle relaxation failure
WO2005020928A3 (en) Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins
WO2007042040A3 (en) TREATMENT OF RETINOPATHIES USING GFRα3 AGONISTS
WO2006024931A3 (en) Therapeutic combinations comprising a selective estrogen receptor modulator and a selective androgen receptor modulator
EP1542664A4 (en) Methods and compositions for treatment of macular and retinal disease
EP1262197A3 (en) Combination treatment for sleep disorders including sleep apnea
MXPA05013104A (en) Method for the treatment or prevention of lower urinary tract symptoms.
WO2005110018A3 (en) Therapies which act on neuropeptide s receptors
WO2004029025A3 (en) Methods and compositions for the treatment of autoimmune disorders using clofarabine
WO2008099804A1 (en) Therapeutic agent for diabetic cataract

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase